Ionis Pharmaceuticals has received $40 million in milestone earnings from Biogen following Japanese regulatory approval of the price of Spinraza, Biogen’s treatment for spinal muscular atrophy.
So far, Ionis has earned more ... Read more
Spinal muscular atrophy (SMA) is a genetic neuromuscular disease. SMA patients have either a missing or altered gene, (the survival motor neuron-1 or SMN1 gene), which causes large motor nerves ... Read more
Game developers will never embrace accessibility — unless they realize how much the medium means to disabled people. So, continuing with the theme of last week’s column, I want ... Read more
Pin It on Pinterest